

ASX MEDIA RELEASE

28 November 2023

On-Sale Cleansing Notice Under Section 708a(5)(E) Corporations Act

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), issued 92,587 fully paid ordinary shares as a result of the exercise of options with an exercise price of \$0.605 per share and 87,969 fully paid ordinary shares as a result of the exercise of options with an exercise price of \$1.125 per share on 23 November 2023 (the "Shares").

Clarity has issued the Shares without disclosure to investors under section 708(5) *Corporations Act 2001* (*Cth*) ("Corporations Act").

For the purposes of section 708A(6) *Corporations Act*, Clarity advises that:

- (a) the Shares have been issued without disclosure to investors under Part 6D.2 *Corporations Act*;
- (b) this notice is given under section 708A(5)(e) *Corporations Act*;
- (c) as at the date of this notice, Clarity has complied with:
 - (i) the provisions of Chapter 2M *Corporations Act* as they apply to Clarity; and
 - (ii) sections 674 and 674A *Corporations Act*; and
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) *Corporations Act* to be disclosed under section 708A(6)(e) *Corporations Act*.

Signed for and on behalf of Clarity

Robert Vickery
Company Secretary

This announcement has been authorised for release by Dr Alan Taylor, Executive Chairman.

For more information, please contact:

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com